PainMESA-VATSNCT07868484
Comparison of the Effectiveness of Midpoint Transverse Process to Pleura (MTP) Block and Erector Spinae Plane (ESP) Block in Video-Assisted Thoracoscopic Surgery (VATS) at RS Ngoerah
A study testing Midpoint Transverse Process to Pleura (MTP) block and Erector spinae plane (ESP) block in people with Pain and Postoperative Pain, run by Udayana University at 1 site in Indonesia.
Trial summary
This randomized, double-blind controlled trial compares two ultrasound-guided fascial plane blocks, the midpoint transverse process to pleura (MTP) block and the erector spinae plane (ESP) block, for postoperative analgesia in adults undergoing elective video-assisted thoracoscopic surgery (VATS) at RS Ngoerah… Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Pain, Postoperative Pain
- What is being tested?
- Midpoint Transverse Process to Pleura (MTP) block and Erector spinae plane (ESP) block
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 51 participants
- Where
- 1 siteIndonesia
- Study dates
- 4 Jun 2026to 4 Oct 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult patients scheduled for elective video-assisted thoracoscopic surgery (VATS) at RS Ngoerah
- Age 18-65 years
- ASA physical status I-III
- Body mass index 18-30 kg/m2
- Able to communicate well in Indonesian, understand the use of the Numerical Rating Scale, and complete the QoR-15 questionnaire
- Willing to participate and has signed written informed consent
Who cannot join
- Contraindication to regional anesthesia
- Allergy to the drugs used (ropivacaine, fentanyl, paracetamol and/or ibuprofen)
- Chronic chest pain for more than 2 months before surgery
- Unable to be assessed with the Numerical Rating Scale and unable to operate the PCA device
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Indonesia1 site, 1 recruiting
- Recruiting
RS Ngoerah
Denpasar, Bali, 80113
Lalu Reza Aldira Akbar, MD, +6281337871680, aldeeraakbar@gmail.com
About this study
Official title: A Randomized, Double-Blind Controlled Trial Comparing the Effectiveness of Midpoint Transverse Process to Pleura (MTP) Block and Erector Spinae Plane (ESP) Block in Video-Assisted Thoracoscopic Surgery (VATS) at RS Ngoerah
This randomized, double-blind controlled trial compares two ultrasound-guided fascial plane blocks, the midpoint transverse process to pleura (MTP) block and the erector spinae plane (ESP) block, for postoperative analgesia in adults undergoing elective video-assisted thoracoscopic surgery (VATS) at RS Ngoerah, Denpasar, Indonesia. Both blocks are performed at the T4-T5 level after induction of general anesthesia and before skin incision, with a single injection of 20 mL ropivacaine 0.375%. Participants are randomly allocated, using block randomization and sealed opaque envelopes, to the MTP block group or the ESP block group. All participants receive the same general anesthesia, the same multimodal analgesia, and the same fentanyl patient-controlled analgesia (PCA) after surgery. The primary outcome is total fentanyl consumption via PCA in the first 24 hours after surgery. Secondary outcomes are numerical rating scale (NRS) pain scores at 0, 1, 2, 4, 6, 12 and 24 hours, time to first rescue analgesia, and Quality of Recovery-15 (QoR-15) score at 24 hours. All outcomes are assessed by the Acute Pain Service team, who are blinded to group allocation. The study tests whether the MTP block, which places local anesthetic closer to the thoracic paravertebral space, differs from the ESP block in these outcomes.
Read the detailed description
Background and rationale Postoperative pain of moderate to severe intensity is still common in the first 24 hours after video-assisted thoracoscopic surgery (VATS) despite its minimally invasive nature. Inadequately treated pain can lead to splinting, atelectasis and chronic post-surgical pain. At RS Ngoerah, postoperative analgesia after VATS is not yet standardized and relies on intravenous systemic opioids or thoracic epidural anesthesia. Ultrasound-guided fascial plane blocks are recommended as components of enhanced recovery protocols.
The erector spinae plane (ESP) block places local anesthetic in the fascial plane between the erector spinae muscle and the transverse process. Analgesia depends mainly on blockade of the dorsal rami, and spread to the thoracic paravertebral space is variable. The midpoint transverse process to pleura (MTP) block places the needle tip midway between the posterior edge of the transverse process and the pleura. It is closer to the thoracic paravertebral space but still posterior to the superior costotransverse ligament, and is expected to give more reliable spread to the paravertebral space, with a theoretically higher risk of pneumothorax than the ESP block. To the investigators' knowledge, no randomized trial has directly compared the two blocks exclusively in VATS, and the Quality of Recovery-15 (QoR-15) has not been compared between them in thoracic surgery.
Study design Randomized, double-blind, parallel-group controlled trial at a single center (Central Surgical Installation, RS Ngoerah, Denpasar, Indonesia) in adult patients undergoing elective VATS. Outcomes are measured only after the intervention, without a baseline measurement, because baseline conditions of the two groups are assumed to be equal through randomization. Participants receive the block after induction of general anesthesia and are therefore unaware of the block type. Outcomes are assessed by the Acute Pain Service (APS) team, who are blinded to group allocation. The blocks are performed by a consultant anesthesiologist (regional analgesia consultant) of the Department of Anesthesiology and Intensive Therapy, RS Ngoerah, who follows the randomization envelope and does not assess outcomes.
Participants and sampling Consecutive sampling of eligible adult patients (age 18-65 years, ASA I-III, BMI 18-30 kg/m2) scheduled for elective VATS. Planned total sample size is 48 participants (24 per group).
Randomization and allocation concealment Block randomization, with the list generated using randomizer.org. The list is kept in sealed, opaque, sequentially numbered envelopes that are opened only by the block operator shortly before the patient enters the operating room, after eligibility is confirmed. The allocated block is recorded by the operator and is not communicated to the assessor or the patient.
Perioperative protocol Preoperative: eligibility screening by the investigator, written informed consent, education on PCA use, and recording of baseline data (age, sex, BMI, ASA status, diagnosis, planned VATS procedure, INR, platelet count, preoperative opioid use) from the medical record and direct measurement.
Intraoperative: standard ASA monitoring. Induction with propofol 1.5-2.0 mg/kg, fentanyl 2 mcg/kg and rocuronium 0.6 mg/kg intravenously, with double-lumen tube intubation as required by the VATS procedure. Maintenance with sevoflurane 0.8-1 MAC and fentanyl 0.5-1 mcg/kg every 30-45 minutes, titrated to hemodynamic response. The block is performed under general anesthesia in the lateral decubitus position, at least 15 minutes before surgical incision (see intervention descriptions). VATS is performed by the thoracic surgery team of RS Ngoerah using standard technique. Ibuprofen 400 mg IV and paracetamol 1 g IV are given 30 minutes before wound closure in all participants.
Postoperative (0-24 hours): fentanyl PCA is started immediately after arrival at the PACU (10 mcg/mL, demand only, demand dose 20 mcg, lockout interval 10 minutes, maximum 200 mcg per 4 hours, no background infusion), programmed identically in both groups. If NRS is 4 or higher at a scheduled assessment, rescue analgesia is a 20 mcg fentanyl bolus delivered through the PCA pump and pressed by the patient. The time of the first rescue is recorded to the minute from nursing records or the PCA log.
Outcome assessment All assessments are made by the blinded APS team. Total PCA fentanyl is read from the cumulative PCA pump log at 24 hours and expressed in mcg/kg. NRS (0-10) at rest and on movement is obtained by guided interview at 0, 1, 2, 4, 6, 12 and 24 hours after the end of surgery. Time to first rescue analgesia is taken from nursing records and the PCA log. The Indonesian version of the QoR-15 is completed by the participant at 24 +/- 2 hours after surgery.
Sample size Sample size per group was calculated with the formula for unpaired numeric comparison (alpha 5%, power 90%) for four outcomes: total PCA fentanyl at 24 hours (16 per group), NRS at 12 hours (16 per group), time to first rescue analgesia (21 per group) and QoR-15 at 24 hours (17 per group). The largest requirement (21 per group) was adopted and, with a 10% drop-out allowance, 24 per group (48 in total) is planned.
Statistical analysis Analysis is per-protocol: only participants who complete the protocol are analyzed. Numeric variables are summarized as mean and standard deviation or median and interquartile range, according to the distribution; categorical variables as frequency and percentage. Normality is tested with the Shapiro-Wilk test and homogeneity of variance with Levene's test. NRS scores at the seven time points are analyzed as repeated measures (repeated-measures ANOVA with group and time factors and the group x time interaction when data are normally distributed; non-parametric Friedman test otherwise). Total PCA fentanyl, time to first rescue analgesia and QoR-15 are compared between groups with the independent t-test, or the Mann-Whitney U test when assumptions are not met. Potential covariates (type of VATS procedure, duration of surgery, duration of anesthesia, intraoperative fentanyl) are included in the comparative analysis if baseline comparability testing shows a significant difference between groups. A p value below 0.05 is considered statistically significant. Software: IBM SPSS Statistics version 25.0 or R version 4.0 or higher.
Withdrawal and drop-out criteria Conversion from VATS to open thoracotomy; technical failure of the regional block confirmed by the operator, so the participant does not receive the intervention as specified; death within the 24-hour follow-up; postoperative mechanical ventilation; complications during care such as local anesthetic systemic toxicity (LAST) or allergic reaction/anaphylaxis; withdrawal from the study at any time during data collection.
Safety monitoring Signs and symptoms of LAST (agitation, seizure, arrhythmia), pneumothorax, and opioid adverse events (respiratory depression, postoperative nausea and vomiting, pruritus) are recorded systematically on the case report form. Serious adverse events are reported to the research ethics committee.
Ethics The protocol was approved by the Research Ethics Committee, Faculty of Medicine, Universitas Udayana (protocol number 2026.02.1.0705, approval date 3 June 2026). Written informed consent is obtained from all participants.
- Conditions
- Pain, Postoperative Pain
- Being tested
- Midpoint Transverse Process to Pleura (MTP) block, Erector spinae plane (ESP) block
- Keywords
- Erector Spinae Plane Block, Midpoint Transverse Process to Pleura Block, MTP Block, ESP Block, Video-Assisted Thoracoscopic Surgery, VATS, Ropivacaine, Fentanyl, Patient-Controlled Analgesia, Quality of Recovery-15, Fascial Plane Block
- Medical subject headings
- Pain, Pain, Postoperative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Midpoint Transverse Process to Pleura (MTP) blockProcedure or surgery
Also called MTP Block
Performed under general anesthesia in the lateral decubitus position, at least 15 minutes before surgical incision. A linear transducer (10-15 MHz) is placed parasagittally 3 cm lateral to the midline at T4-T5, and the transverse process and pleura are identified. The midpoint between the posterior edge of the transverse process and the pleura is determined. A 22G echogenic needle is advanced in-plane from cranial to caudal until the tip reaches the midpoint. After 1 mL normal saline confirms fascial separation, ropivacaine 0.375% 20 mL is injected in increments with intermittent aspiration every 5 mL. Correct placement is confirmed by fascial spread and pleural displacement on real-time ultrasound. Performed by a consultant anesthesiologist (regional analgesia).
Erector spinae plane (ESP) blockProcedure or surgery
Also called ESP block
Performed under general anesthesia in the lateral decubitus position, at least 15 minutes before surgical incision. A linear transducer (10-15 MHz) is placed parasagittally 3 cm lateral to the midline at T4-T5, and the transverse process and the erector spinae muscle are identified. A 22G echogenic needle is advanced in-plane from caudal to cranial until the tip lies beneath the erector spinae muscle, just above the surface of the transverse process. A 1 mL normal saline injection produces the lift sign (erector spinae muscle lifted off the transverse process), then ropivacaine 0.375% 20 mL is injected gradually. Performed by a consultant anesthesiologist (regional analgesia).
| Study group | Role | What they receive |
|---|---|---|
| MTP block | Experimental | Ultrasound-guided MTP block with ropivacaine 0.375% 20 mL single injection at T4-T5, performed under general anesthesia in the lateral decubitus position at least 15 minutes before incision. All participants also receive the same general anesthesia, ibuprofen 400 mg IV and paracetamol 1 g IV 30 minutes before wound closure, and postoperative fentanyl PCA (10 mcg/mL, demand dose 20 mcg, lockout 10 minutes, no background infusion). Receives: Procedure: Midpoint Transverse Process to Pleura (MTP) block |
| ESP block | Experimental | Ultrasound-guided ESP block with ropivacaine 0.375% 20 mL single injection at T4-T5, performed under general anesthesia in the lateral decubitus position at least 15 minutes before incision. All participants also receive the same general anesthesia, ibuprofen 400 mg IV and paracetamol 1 g IV 30 minutes before wound closure, and postoperative fentanyl PCA (10 mcg/mL, demand dose 20 mcg, lockout 10 minutes, no background infusion). Receives: Procedure: Erector spinae plane (ESP) block |
What is being measured
The primary outcome is the main question the study is designed to answer.
Total fentanyl consumption via patient-controlled analgesia (PCA) in the first 24 hours after surgery
Cumulative fentanyl dose delivered through the PCA pump over the first 24 hours after surgery, read from the cumulative PCA pump log at 24 hours and expressed in mcg per kg body weight. PCA settings: fentanyl 10 mcg/mL, demand only, demand dose 20 mcg, lockout interval 10 minutes, maximum 200 mcg per 4 hours, no background infusion, identical in both groups.
Measured: 24 hours after surgery
Secondary outcomes (3)
Postoperative pain intensity (Numerical Rating Scale, 0-10)
Postoperative pain intensity (Numerical Rating Scale, 0-10)
Measured: Self-reported pain intensity on the Numerical Rating Scale (0 = no pain, 10 = worst pain imaginable), obtained by guided interview by a blinded Acute Pain Service assessor.
Time to first rescue analgesia
Time in minutes from arrival at the Post-Anesthesia Care Unit (PACU) until the participant first requires rescue analgesia for pain with NRS of 4 or higher, taken from nursing records and the PCA pump log by a blinded assessor. Rescue analgesia is a 20 mcg fentanyl bolus delivered through the PCA pump. Participants who need no rescue analgesia within 24 hours are recorded as 1440 minutes.
Measured: Up to 24 hours after surgery
Quality of Recovery-15 (QoR-15) score
Total score of the 15-item patient-reported Quality of Recovery questionnaire (Indonesian version), each item scored 0-10, total 0-150 (higher score = better recovery), completed by the participant and assessed by a blinded assessor.
Measured: 24 +/- 2 hours after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Oct 2026
- Study start4 Jun 2026
- Primary completion3 Sep 2026
- Study completion4 Oct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PainStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Two-arm, parallel-group randomized trial with block randomization. Each participant receives either an ultrasound-guided MTP block or an ultrasound-guided ESP block (ropivacaine 0.375% 20 mL, single injection, T4-T5) after induction of general anesthesia.
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 51 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Udayana University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Lalu Reza Aldira Akbar, Udayana University
- Investigators
- Tjokorda Gde Agung Senapathi, Professor, Study chair, Udayana UniversityPutu Herdita Sudiantara, Sp.An-TI, Study director, Udayana University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07868484
- Sponsor's protocol ID
- 2026.02.1.0705
- Other IDs
- 2310/UN14.2.2.VII.14/LT/2026
- Acronym
- MESA-VATS
- Status last verified
- Oct 2026
- First submitted
- 5 Oct 2026
- Last updated
- 9 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared with other researchers. The written informed consent given to participants states that their identity and medical data are kept confidential and can only be accessed by the research team and authorized parties for ethics audit. Aggregate results will be reported in the thesis and publications without participant identities.
Study at a glance
From the registry record, last updated by the sponsor on 9 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind Controlled Trial Comparing the Effectiveness of Midpoint Transverse Process to Pleura (MTP) Block and Erector Spinae Plane (ESP) Block in Video-Assisted Thoracoscopic Surgery (VATS) at RS Ngoerah
- ClinicalTrials.gov ID
- NCT07868484
- Acronym / sponsor ID
- MESA-VATS / 2026.02.1.0705
- Conditions
- Pain, Postoperative Pain
- Keywords
- Erector Spinae Plane Block, Midpoint Transverse Process to Pleura Block, MTP Block, ESP Block, Video-Assisted Thoracoscopic Surgery, VATS, Ropivacaine, Fentanyl
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 51 participants (estimated)
- Lead sponsor
- Udayana UniversityUniversity, hospital or other
- Study start
- 4 Jun 2026 (actual)
- Primary completion
- 3 Sep 2026 (actual)
- Study completion
- 4 Oct 2026 (estimated)
- First posted
- 9 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized, double-blind controlled trial compares two ultrasound-guided fascial plane blocks, the midpoint transverse process to pleura (MTP) block and the erector spinae plane (ESP) block, for postoperative analgesia in adults undergoing elective video-assisted thoracoscopic surgery (VATS) at RS Ngoerah, Denpasar, Indonesia. Both blocks are performed at the T4-T5 level after induction of general anesthesia and before skin incision, with a single injection of 20 mL ropivacaine 0.375%. Participants are randomly allocated, using block randomization and sealed opaque envelopes, to the MTP block group or the ESP block group. All participants receive the same general anesthesia, the same multimodal analgesia, and the same fentanyl patient-controlled analgesia (PCA) after surgery. The primary outcome is total fentanyl consumption via PCA in the first 24 hours after surgery. Secondary outcomes are numerical rating scale (NRS) pain scores at 0, 1, 2, 4, 6, 12 and 24 hours, time to first rescue analgesia, and Quality of Recovery-15 (QoR-15) score at 24 hours. All outcomes are assessed by the Acute Pain Service team, who are blinded to group allocation. The study tests whether the MTP block, which places local anesthetic closer to the thoracic paravertebral space, differs from the ESP block in these outcomes.
Detailed description
Background and rationale Postoperative pain of moderate to severe intensity is still common in the first 24 hours after video-assisted thoracoscopic surgery (VATS) despite its minimally invasive nature. Inadequately treated pain can lead to splinting, atelectasis and chronic post-surgical pain. At RS Ngoerah, postoperative analgesia after VATS is not yet standardized and relies on intravenous systemic opioids or thoracic epidural anesthesia. Ultrasound-guided fascial plane blocks are recommended as components of enhanced recovery protocols.
The erector spinae plane (ESP) block places local anesthetic in the fascial plane between the erector spinae muscle and the transverse process. Analgesia depends mainly on blockade of the dorsal rami, and spread to the thoracic paravertebral space is variable. The midpoint transverse process to pleura (MTP) block places the needle tip midway between the posterior edge of the transverse process and the pleura. It is closer to the thoracic paravertebral space but still posterior to the superior costotransverse ligament, and is expected to give more reliable spread to the paravertebral space, with a theoretically higher risk of pneumothorax than the ESP block. To the investigators' knowledge, no randomized trial has directly compared the two blocks exclusively in VATS, and the Quality of Recovery-15 (QoR-15) has not been compared between them in thoracic surgery.
Study design Randomized, double-blind, parallel-group controlled trial at a single center (Central Surgical Installation, RS Ngoerah, Denpasar, Indonesia) in adult patients undergoing elective VATS. Outcomes are measured only after the intervention, without a baseline measurement, because baseline conditions of the two groups are assumed to be equal through randomization. Participants receive the block after induction of general anesthesia and are therefore unaware of the block type. Outcomes are assessed by the Acute Pain Service (APS) team, who are blinded to group allocation. The blocks are performed by a consultant anesthesiologist (regional analgesia consultant) of the Department of Anesthesiology and Intensive Therapy, RS Ngoerah, who follows the randomization envelope and does not assess outcomes.
Participants and sampling Consecutive sampling of eligible adult patients (age 18-65 years, ASA I-III, BMI 18-30 kg/m2) scheduled for elective VATS. Planned total sample size is 48 participants (24 per group).
Randomization and allocation concealment Block randomization, with the list generated using randomizer.org. The list is kept in sealed, opaque, sequentially numbered envelopes that are opened only by the block operator shortly before the patient enters the operating room, after eligibility is confirmed. The allocated block is recorded by the operator and is not communicated to the assessor or the patient.
Perioperative protocol Preoperative: eligibility screening by the investigator, written informed consent, education on PCA use, and recording of baseline data (age, sex, BMI, ASA status, diagnosis, planned VATS procedure, INR, platelet count, preoperative opioid use) from the medical record and direct measurement.
Intraoperative: standard ASA monitoring. Induction with propofol 1.5-2.0 mg/kg, fentanyl 2 mcg/kg and rocuronium 0.6 mg/kg intravenously, with double-lumen tube intubation as required by the VATS procedure. Maintenance with sevoflurane 0.8-1 MAC and fentanyl 0.5-1 mcg/kg every 30-45 minutes, titrated to hemodynamic response. The block is performed under general anesthesia in the lateral decubitus position, at least 15 minutes before surgical incision (see intervention descriptions). VATS is performed by the thoracic surgery team of RS Ngoerah using standard technique. Ibuprofen 400 mg IV and paracetamol 1 g IV are given 30 minutes before wound closure in all participants.
Postoperative (0-24 hours): fentanyl PCA is started immediately after arrival at the PACU (10 mcg/mL, demand only, demand dose 20 mcg, lockout interval 10 minutes, maximum 200 mcg per 4 hours, no background infusion), programmed identically in both groups. If NRS is 4 or higher at a scheduled assessment, rescue analgesia is a 20 mcg fentanyl bolus delivered through the PCA pump and pressed by the patient. The time of the first rescue is recorded to the minute from nursing records or the PCA log.
Outcome assessment All assessments are made by the blinded APS team. Total PCA fentanyl is read from the cumulative PCA pump log at 24 hours and expressed in mcg/kg. NRS (0-10) at rest and on movement is obtained by guided interview at 0, 1, 2, 4, 6, 12 and 24 hours after the end of surgery. Time to first rescue analgesia is taken from nursing records and the PCA log. The Indonesian version of the QoR-15 is completed by the participant at 24 +/- 2 hours after surgery.
Sample size Sample size per group was calculated with the formula for unpaired numeric comparison (alpha 5%, power 90%) for four outcomes: total PCA fentanyl at 24 hours (16 per group), NRS at 12 hours (16 per group), time to first rescue analgesia (21 per group) and QoR-15 at 24 hours (17 per group). The largest requirement (21 per group) was adopted and, with a 10% drop-out allowance, 24 per group (48 in total) is planned.
Statistical analysis Analysis is per-protocol: only participants who complete the protocol are analyzed. Numeric variables are summarized as mean and standard deviation or median and interquartile range, according to the distribution; categorical variables as frequency and percentage. Normality is tested with the Shapiro-Wilk test and homogeneity of variance with Levene's test. NRS scores at the seven time points are analyzed as repeated measures (repeated-measures ANOVA with group and time factors and the group x time interaction when data are normally distributed; non-parametric Friedman test otherwise). Total PCA fentanyl, time to first rescue analgesia and QoR-15 are compared between groups with the independent t-test, or the Mann-Whitney U test when assumptions are not met. Potential covariates (type of VATS procedure, duration of surgery, duration of anesthesia, intraoperative fentanyl) are included in the comparative analysis if baseline comparability testing shows a significant difference between groups. A p value below 0.05 is considered statistically significant. Software: IBM SPSS Statistics version 25.0 or R version 4.0 or higher.
Withdrawal and drop-out criteria Conversion from VATS to open thoracotomy; technical failure of the regional block confirmed by the operator, so the participant does not receive the intervention as specified; death within the 24-hour follow-up; postoperative mechanical ventilation; complications during care such as local anesthetic systemic toxicity (LAST) or allergic reaction/anaphylaxis; withdrawal from the study at any time during data collection.
Safety monitoring Signs and symptoms of LAST (agitation, seizure, arrhythmia), pneumothorax, and opioid adverse events (respiratory depression, postoperative nausea and vomiting, pruritus) are recorded systematically on the case report form. Serious adverse events are reported to the research ethics committee.
Ethics The protocol was approved by the Research Ethics Committee, Faculty of Medicine, Universitas Udayana (protocol number 2026.02.1.0705, approval date 3 June 2026). Written informed consent is obtained from all participants.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- Two-arm, parallel-group randomized trial with block randomization. Each participant receives either an ultrasound-guided MTP block or an ultrasound-guided ESP block (ropivacaine 0.375% 20 mL, single injection, T4-T5) after induction of general anesthesia.
| Arm | Type | Receives |
|---|---|---|
| MTP block | Experimental | Procedure: Midpoint Transverse Process to Pleura (MTP) blockUltrasound-guided MTP block with ropivacaine 0.375% 20 mL single injection at T4-T5, performed under general anesthesia in the lateral decubitus position at least 15 minutes before incision. All participants also receive the same general anesthesia, ibuprofen 400 mg IV and paracetamol 1 g IV 30 minutes before wound closure, and postoperative fentanyl PCA (10 mcg/mL, demand dose 20 mcg, lockout 10 minutes, no background infusion). |
| ESP block | Experimental | Procedure: Erector spinae plane (ESP) blockUltrasound-guided ESP block with ropivacaine 0.375% 20 mL single injection at T4-T5, performed under general anesthesia in the lateral decubitus position at least 15 minutes before incision. All participants also receive the same general anesthesia, ibuprofen 400 mg IV and paracetamol 1 g IV 30 minutes before wound closure, and postoperative fentanyl PCA (10 mcg/mL, demand dose 20 mcg, lockout 10 minutes, no background infusion). |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Adult patients scheduled for elective video-assisted thoracoscopic surgery (VATS) at RS Ngoerah
- Age 18-65 years
- ASA physical status I-III
- Body mass index 18-30 kg/m2
- Able to communicate well in Indonesian, understand the use of the Numerical Rating Scale, and complete the QoR-15 questionnaire
Key exclusion criteria (4 listed)
- Contraindication to regional anesthesia
- Allergy to the drugs used (ropivacaine, fentanyl, paracetamol and/or ibuprofen)
- Chronic chest pain for more than 2 months before surgery
- Unable to be assessed with the Numerical Rating Scale and unable to operate the PCA device
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Midpoint Transverse Process to Pleura (MTP) blockAlso: MTP BlockPerformed under general anesthesia in the lateral decubitus position, at least 15 minutes before surgical incision. A linear transducer (10-15 MHz) is placed parasagittally 3 cm lateral to the midline at T4-T5, and the transverse process and pleura are identified. The midpoint between the posterior edge of the transverse process and the pleura is determined. A 22G echogenic needle is advanced in-plane from cranial to caudal until the tip reaches the midpoint. After 1 mL normal saline confirms fascial separation, ropivacaine 0.375% 20 mL is injected in increments with intermittent aspiration every 5 mL. Correct placement is confirmed by fascial spread and pleural displacement on real-time ultrasound. Performed by a consultant anesthesiologist (regional analgesia). | Procedure or surgery | MTP block |
| Erector spinae plane (ESP) blockAlso: ESP blockPerformed under general anesthesia in the lateral decubitus position, at least 15 minutes before surgical incision. A linear transducer (10-15 MHz) is placed parasagittally 3 cm lateral to the midline at T4-T5, and the transverse process and the erector spinae muscle are identified. A 22G echogenic needle is advanced in-plane from caudal to cranial until the tip lies beneath the erector spinae muscle, just above the surface of the transverse process. A 1 mL normal saline injection produces the lift sign (erector spinae muscle lifted off the transverse process), then ropivacaine 0.375% 20 mL is injected gradually. Performed by a consultant anesthesiologist (regional analgesia). | Procedure or surgery | ESP block |
Primary outcome
Total fentanyl consumption via patient-controlled analgesia (PCA) in the first 24 hours after surgery
Time frame: 24 hours after surgery
Cumulative fentanyl dose delivered through the PCA pump over the first 24 hours after surgery, read from the cumulative PCA pump log at 24 hours and expressed in mcg per kg body weight. PCA settings: fentanyl 10 mcg/mL, demand only, demand dose 20 mcg, lockout interval 10 minutes, maximum 200 mcg per 4 hours, no background infusion, identical in both groups.
3 secondary outcomes
Postoperative pain intensity (Numerical Rating Scale, 0-10)
Time frame: Self-reported pain intensity on the Numerical Rating Scale (0 = no pain, 10 = worst pain imaginable), obtained by guided interview by a blinded Acute Pain Service assessor.
Time to first rescue analgesia
Time frame: Up to 24 hours after surgery
Quality of Recovery-15 (QoR-15) score
Time frame: 24 +/- 2 hours after surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Oct 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be shared with other researchers. The written informed consent given to participants states that their identity and medical data are kept confidential and can only be accessed by the research team and authorized parties for ethics audit. Aggregate results will be reported in the thesis and publications without participant identities.
Related trials for Pain
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Recruiting
Empowered Relief® for Cancer Survivors With Chronic Pain
Chronic Pain Due to Cancer, Pain Catastrophizing
RecruitingPhase 4
ESP Blocks for Posterior Spinal Fusion
Postoperative Pain
RecruitingObservational study
Pain Phenotypes in Individuals With Multiple Sclerosis
Multiple Sclerosis, Chronic Pain
Not yet recruiting
Effects of Hip Hinge Exercises on Pain, Range of Motion and Functional Disability in Non-specific Low Back Pain.
Low Back Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Tjokorda Gde Agung Senapathi, Professor study chair
Udayana University
Putu Herdita Sudiantara, Sp.An-TI study director
Udayana University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Midpoint Transverse Process to Pleura (MTP) block and Erector spinae plane (ESP) block in people with Pain and Postoperative Pain, run by Udayana University at 1 site in Indonesia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 9 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Indonesia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lalu Reza Aldira Akbar, MD (+6281337871680, aldeeraakbar@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total fentanyl consumption via patient-controlled analgesia (PCA) in the first 24 hours after surgery (time frame: 24 hours after surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Oct 2026.